Severe persistent visual field constriction associated with vigabatrin: asymptomatic as well as symptomatic defects occur with vigabatrin

R. Mackenzie; A. Klistorner

Severe persistent visual field constriction associated with vigabatrin

asymptomatic as well as symptomatic defects occur with vigabatrin

R. Mackenzie^*, A. Klistorner

^*Corresponding author for this work

Department of Clinical Medicine

Research output: Contribution to journal › Comment/opinion

48 Citations (Scopus)

Abstract

Editor—Since Eke et al's report of symptomatic visual field defects in three patients taking vigabatrin, a drug surveillance database at Hoechst Marion Roussel had identified another 92 cases by June 1997. Asymptomatic visual field defects may be
more common, but the exact incidence is unknown and data on the results of field
testing and electrophysiology are lacking in this group. We report these results in two asymptomatic patients.

Original language	English
Pages (from-to)	233
Number of pages	1
Journal	BMJ (Clinical research ed.)
Volume	316
Issue number	7126
Publication status	Published - 1998

Access to Document

Fingerprint Dive into the research topics of 'Severe persistent visual field constriction associated with vigabatrin: asymptomatic as well as symptomatic defects occur with vigabatrin'. Together they form a unique fingerprint.

Cite this

Mackenzie, R., & Klistorner, A. (1998). Severe persistent visual field constriction associated with vigabatrin: asymptomatic as well as symptomatic defects occur with vigabatrin. BMJ (Clinical research ed.), 316(7126), 233.

@article{e4db1542fcb1418abeba26079e866e14,

title = "Severe persistent visual field constriction associated with vigabatrin: asymptomatic as well as symptomatic defects occur with vigabatrin",

abstract = "Editor—Since Eke et al's report of symptomatic visual field defects in three patients taking vigabatrin, a drug surveillance database at Hoechst Marion Roussel had identified another 92 cases by June 1997. Asymptomatic visual field defects may bemore common, but the exact incidence is unknown and data on the results of fieldtesting and electrophysiology are lacking in this group. We report these results in two asymptomatic patients.",

author = "R. Mackenzie and A. Klistorner",

year = "1998",

language = "English",

volume = "316",

pages = "233",

journal = "BMJ (Online)",

issn = "0959-8138",

publisher = "BMJ Publishing Group",

number = "7126",

}

TY - JOUR

T1 - Severe persistent visual field constriction associated with vigabatrin

T2 - asymptomatic as well as symptomatic defects occur with vigabatrin

AU - Mackenzie, R.

AU - Klistorner, A.

PY - 1998

Y1 - 1998

N2 - Editor—Since Eke et al's report of symptomatic visual field defects in three patients taking vigabatrin, a drug surveillance database at Hoechst Marion Roussel had identified another 92 cases by June 1997. Asymptomatic visual field defects may bemore common, but the exact incidence is unknown and data on the results of fieldtesting and electrophysiology are lacking in this group. We report these results in two asymptomatic patients.

AB - Editor—Since Eke et al's report of symptomatic visual field defects in three patients taking vigabatrin, a drug surveillance database at Hoechst Marion Roussel had identified another 92 cases by June 1997. Asymptomatic visual field defects may bemore common, but the exact incidence is unknown and data on the results of fieldtesting and electrophysiology are lacking in this group. We report these results in two asymptomatic patients.

UR - http://www.scopus.com/inward/record.url?scp=0032539293&partnerID=8YFLogxK

M3 - Comment/opinion

VL - 316

SP - 233

JO - BMJ (Online)

JF - BMJ (Online)

SN - 0959-8138

IS - 7126

ER -